Pernod Ricard vs Sanofi

Pernod Ricard Files 2025/26 Universal Registration Document and Reports FY26 Full-year Sales and Results

New press releases and publications include the filing of the 2025/26 Universal Registration Document (16/09/2026) and the FY26 Full-year Sales and Results (27/08/2026), along with an upcoming Q1 FY27 Sales event on 15 October 2026.

Jamiroquai Recreates 'Virtual Insanity' for Beefeater 0.0%

Beefeater partnered with Jamiroquai to recreate the 'Virtual Insanity' video for its alcohol-free Beefeater 0.0, timed with the song's 30th anniversary. Lucky Generals conceived the campaign; the 122-second hero film was directed by Paris duo Julien & Quentin and produced by Magna Studios, with frontman Jay Kay choreographing. The production eschewed CGI and AI, building nine physically moving rooms and relying on in-camera choreography and set design. Launched online in July, the campaign positions 0.0 as a moderation choice—leaning on the 'zebra striping' trend—and runs across key markets including the UK, Spain and Italy. Support includes social and Out-of-Home activity, influencer and community engagement (Reddit, Discord), bespoke bottles, a video-game element and behind-the-scenes content; Francesco Ottaviano of Pernod Ricard framed the effort as promoting moderate drinking.

• Beefeater partnered with Jamiroquai to recreate 'Virtual Insanity' for Beefeater 0.0 on the song's 30th anniversary.
• Campaign conceived by Lucky Generals; 122-second film directed by Julien & Quentin and produced by Magna Studios; Jay Kay choreographed.
• Production used nine physically moving rooms and in-camera choreography; no CGI or AI.

6-K Financial Filing Analysis for Sanofi (2026-09-17)

Am 17. September 2026 reichte Sanofi ein Form 6-K bei der U.S. Securities and Exchange Commission ein, das eine Pressemitteilung vom 14. September 2026 beinhaltet. Die Einreichung kündigt eine neue strategische Partnerschaft zwischen Sanofi und Cheplapharm im Bereich etablierter Medikamente (Mature Medicines) an. Diese Partnerschaft unterstreicht Sanofis kontinuierliche Strategie zur Portfolio-Optimierung, um etablierte pharmazeutische Produkte effizienter zu verwalten oder zu monetarisieren und Ressourcen auf innovative Pipeline-Therapien und Kernwachstumstreiber zu fokussieren.

• Sanofi hat eine strategische Partnerschaft mit Cheplapharm für sein Portfolio an etablierten Medikamenten (Mature Medicines) geschlossen, die am 14. September 2026 per Pressemitteilung bekannt gegeben wurde.
• Die Form 6-K-Meldung wurde am 17. September 2026 offiziell von Alexandra Roger, Head of Legal Corporate & Finance, unterzeichnet und eingereicht.

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Agentic AI Transforming Pharma Marketing for Rare Diseases

This article discusses how agentic AI is poised to revolutionize pharmaceutical marketing, particularly for rare disease treatments. With traditional drug development costing $2.6 billion and taking 12-15 years, AI is compressing discovery timelines and enabling treatments for smaller patient populations, with rare disease approvals now exceeding 50% of FDA approvals. However, this precision medicine creates a marketing challenge: reaching small, specific audiences efficiently. The article argues that while programmatic advertising optimized campaign execution, agentic AI can synthesize vast healthcare, audience, and market data to provide actionable commercial insights, forecast patient need, and continuously adapt strategies. Early tests show marketing planning cycles collapsing by up to 10x. This approach aims to make more treatments commercially viable, improving treatment economics and driving further investment.

• The pharma industry invests $2.6 billion on average to bring a new treatment to market, taking 12 to 15 years with a 10% success rate.
• Rare disease approvals now account for over 50% of FDA drug approvals, up from below 30% a decade ago.
• Sanofi is developing a 'lab-in-a-loop' using AI agents to compress discovery work from years to weeks.